In the recent years, artificial intelligence and machine learning (AI/ML) has paved the way for groundbreaking medical innovations and advancements in the life sciences industry. Now the emergence of generative artificial intelligence (GenAI) has been a boon for life sciences companies. So much so that several leaders consider GenAI a paradigm shift in the industry.
In fact, many of the global organizations are walking the talk by tapping into the power of generative AI in life sciences. Be it drug discovery or personalized medicine or patient safety or gene design, firms are embracing generative AI in life sciences to revolutionize the way clinical research is carried out. As per a report, the top technology investment for 60% of life sciences companies is in AI/ML, with 54% of them already using AI/ML.
Harnessing the transformative potential of generative AI in life sciences will not only shape the future of the field but will also drive innovations that can save many lives. In this blog, we will explore and learn about a few of the organizations that are leveraging the potential of generative AI in life sciences to make the world a better place to live in.
Organizations Using Generative AI in Life Sciences:
Besides helping tackle many operational and administrative challenges, GenAI has a host of use cases and applications in the life sciences sector such as transforming the clinical workflows, simplifying search and summarization of electronic health records, accelerating drug discovery, etc. Here are some of the companies that are leveraging generative AI in life sciences.
a). Illumina
Illumina is one of the organizations that are using generative AI in life sciences. The biotech company has recently introduced its AI-powered software that can predict disease-causing genetic alterations in patients. By incorporating several technologies including GenAI, the firm is streamlining the process of uncovering disease-causing mutations, thus opening the doors for personalized treatments, and many other applications. This innovative approach is a significant leap forward in employing generative AI in life sciences.
b). Merck:
Among the organizations leveraging generative AI in life sciences, Merck & Co. is currently exploring Variational AI’s GenAI platform for drug discovery. Variational’s Enki technology generates small molecules based on target product profiles (TPPs), providing novel lead-like structures. Unlike other platforms, Enki doesn’t require users to develop their own AI models. Merck is one of the early adopters of generative AI in life sciences, reflecting the industry’s shift towards AI-driven drug discovery.
c). Bayer Pharma
Bayer Pharma is employing generative AI in life sciences to improve clinical trial processes. The company is leveraging GenAI solutions such as Google Cloud’s Vertex AI and Med-PaLM 2 to streamline the drug development process. By harnessing the power of generative AI, researchers can access, identify, and correlate data with utmost efficiency from vast datasets. With ongoing efforts to leverage high-performance computing, Bayer aims to further enhance drug discovery efforts with GenAI and drive innovation.
d). Biomatter
Out of all the organizations using generative AI in life sciences, Lithuania-based Biomatter Design’s approach differs. The biotech company pioneers synthetic biology with their intelligent Architecture™ platform by integrating GenAI and physical modelling. Pushing the boundaries of synthetic biology, they create novel and functional enzymes via their GPU-powered algorithm ProteinGAN. The company’s pioneering work showcases the revolutionary power of generative AI in life sciences.
e). Peptilogics
The Nautilus™ platform by Peptilogics is among the best instances of the power of generative AI in life sciences. Powered by the N4 supercomputer and equipped with NVIDIA GPUs, the platform is for peptide drug design and optimization. The integration of their proprietary peptide representation and generative algorithms with computational chemistry and biophysics improves the efficiency of peptide-based therapeutics, representing a significant advancement in drug development.
f). HCA Healthcare:
Like Bayer, HCA Healthcare is leveraging generative AI in life sciences in collaboration with Google Cloud. But the organization’s objective behind this initiative is to alleviate the documentation burden for healthcare providers by extracting information from physician-patient conversations to generate draft clinical notes automatically with AI. Upon review and finalization of notes by physicians, they are then integrated into EHRs, thus eliminating manual entry. HCA is also exploring AI solutions to standardize patient handoffs between nurses to promote patient safety and clinical quality.
g). Evozyne:
Chicago-based Evozyne is making progressive strides with generative AI in life sciences. Built on the NVIDIA BioNeMo framework, its powerful AI model called Protein Transformer Variational AutoEncoder (ProT-VAE) can be utilized to create high-quality synthetic proteins that helps design new therapeutic targets for untreatable diseases and slashes drug development time by an impressive margin.
h). Inductive Quotient Analytics (IQA):
Sponsors and CROs struggle with many issues to select the ideal site for their clinical trials. To help simplify the site selection process, Hyderabad-based ClinTech company Inductive Quotient Analytics (IQA) has come up with their very own GenAI platform called Site Insights. A prime innovation in the field of generative AI in life sciences, the solution recommends ideal trial sites from across the world tailored to specific study needs. This can help the industry in efficiently navigating the challenges in bringing life-saving treatments to the market faster.
Please learn more about Site Insights or reach out to us at hello@inductivequoteint.com for a demo.